Navigation Links
Global Growth Factors ( Blood And Tissue ) Industry
Date:3/16/2011

NEW YORK, March 16, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Growth Factors ( Blood And Tissue ) Industry

http://www.reportlinker.com/p0397766/Global-Growth-Factors--Blood-And-Tissue--Industry.html

This report analyzes the worldwide markets for Growth Factors (Blood And Tissue) in US$ Million by the following growth factor types: Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins), and Tissue Growth Factors. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report profiles 88 companies including many key and niche players such as Alseres Pharmaceuticals, Inc., Amgen, Inc., Bayer HealthCare Pharmaceuticals Inc., BioMimetic Therapeutics, Inc., Biopharm GmbH, Bolder Biotechnology, Inc., Ceregene Inc., FibroGen Inc., FzioMed Inc., Novo Nordisk A/S, Reliance GeneMedix Plc, Insmed Inc., Johnson & Johnson, Janssen-Ortho, Inc., Lonza Group, Maxygen, Inc., Merck Serono International S.A., NsGene A/S, PeproTech, Inc., Rentschler Biotechnologie GmbH, F. Hoffmann-La Roche Ltd., Chugai Pharmaceutical Co. Ltd., Genentech, Inc., Shantha Biotechnics, Scil Proteins GmbH, and Wockhardt Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

GROWTH FACTORS (BLOOD AND TISSUE) MCP-1217

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 2

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

Blood Growth Factors 4

Erythropoietins 4

Colony Stimulating Factors 4

Interferons 4

Interleukins 4

Tissue Growth Factors 4

2. INTRODUCTION 6

Growth Factors: A Preface 6

Current and Future Analysis 6

Analysis By Region 6

US - The Single Largest Market 6

Growth Factors Market in Europe 6

Market for Growth Factors in Rest of World 6

Table 1: World Market for Growth Factors (2007-2015):

Geographic Regions Ranked by CAGR - US, Japan, Rest of

World, and Europe (includes corresponding Graph/Chart) 7

Analysis by Growth Factor Type 7

Growth Factors: Their Role and Related Applications 8

Growth Factors: Adding a New Dimension 8

Growth Factors: Classification Based on Activity 8

Recent Trends & Developments 8

Recombinant Human Erythropoietin: Gradually Gaining Dominance 9

Leading EPO Drugs Worldwide 9

Market Comparison of Erythropoietin-Based Drugs in America

and European Union 9

Patent Expiries of Major Biopharmaceutical Drugs: 2001-2007 10

Patent Expiries of Select Biopharmaceuticals in Europe

and United States: 2010 and Beyond 10

3. MARKET DYNAMICS 11

Major Companies Impacted by Patent Expiries 11

Patent Expiries Fuel Competition and Sales 11

Side Effects - Still a Concern 11

CDER- A Regulatory Review Authority for Growth Factors 11

Innovative Delivery System Shows Potential for Accelerating

Use of Growth Factors 12

Cytokines- Vital Growth Propellers for the Future of New Drugs 12

Brain Derived Neurotrophic Factor (BDNF) Finds Increased

Application 12

Age-Related Diseases - Their Influence on Effective Therapies 12

Mimetic Growth Factors - Exhibiting Promising Potential 13

India - At the Center Stage 13

4. INDUSTRY ISSUES 14

Development of Cost Effective Methods - Need of the Hour 14

Influence of Neurotrophic Factors on Brain Cell Development 14

Combination of Interferons and Ribavirin Develops More Anemia

Cases 14

5. GROWTH FACTORS - AN OVERVIEW 15

Blood Growth Factors 15

Erythropoietins 15

Types of Erythropoietins 16

Epoetin 16

Darbepoetin 16

Aranesp® 16

Aranesp Vs. Other EPOs 16

Recombinant Human EPO (rHuEPO) 16

Table 2: World Market for Erythropoietins (2007-2015):

Geographic Regions Ranked by CAGR -Rest of World, Japan, US

and Europe (includes corresponding Graph/Chart) 17

Colony Stimulating Factors 17

Granulocyte-Colony Stimulating Factor 17

Granulocyte Macrophage-Colony Stimulating Factor 18

Other Colony Stimulating Factors 18

Macrophage Colony Stimulating Factor (M-CSF) 18

Key Functions of M-CSF 18

Side-Effects of Colony-Stimulating Factors 18

Table 3: World Market for Colony Stimulating Factors

(2007-2015): Geographic Regions Ranked by CAGR - Europe,

US, Japan and Rest of World (includes corresponding

Graph/Chart) 19

Interferons 19

Types of Interferons 19

Interferon-gamma 20

1a and 1b: Two Key Biochemical Forms of Interferon-ß 20

PEG-Intron 20

Types of Interferons 20

Table 4: World Market for Interferons as Blood Growth

Factors (2007-2015): Geographic Regions Ranked by CAGR -

US, Europe, Japan, and Rest of World (includes

corresponding Graph/Chart) 21

Interleukins 21

Types of Interleukins 21

Table 5: World Market for Interleukins as Blood Growth

Factors (2007-2015): Geographic Regions Ranked by CAGR -

Europe, Rest of World, Japan and US (includes corresponding

Graph/Chart) 22

Tissue Growth Factors 23

Wound Healing Growth Factors 23

Neurotrophic Growth Factors 23

Nerve Growth Factor 23

Vascular Endothelial Growth Factor (VEGF) 23

Fibroblast Growth Factor (FGF) 24

Insulin-Like Growth Factor-I (IGF-I) 24

Insulin-Like Growth Factor-II (IGF-II) 24

Tissue Growth Factors: Classification Based on Key Source

and Principal Activity 24

Platelet - Derived Growth Factors in Wound Healing 24

Thrombopoietin (TPO) 25

Table 6: World Market for Tissue Growth Factors

(2007-2015): Geographic Regions Ranked by CAGR - US,

Europe, Japan, and Rest of World (includes corresponding

Graph/Chart) 25

Growth Factors: Their Mode of Action in Tissue Repair 25

Angiogenesis: Their Role in Wound Healing 26

Angiogenesis As an Alternative for Cardiac Stents 26

Applications of Growth Factors 26

Growth Factors: Suppliers and Applications 27

Growth Factors: Site/Course of Action and Applications 27

6. RESEARCH AND DEVELOPMENT HIGHLIGHTS A RECENT PAST PERSPECTIVE 28

Maxygen Updates on Factor VII Program 28

Evaluation of Extended Dosing Schedule of PROCRIT® 28

PROCRIT® - A Better Option 28

Nerve Growth Factor Shows Promising Potential Against Diabetes 28

Cytokines and GM-CSF Found to be Closely Interlinked 29

GM-CSF Enhances Rate of Survival in Neonates 29

rG-CSF Well Tolerated in Pneumonia and Severe Sepsis Patients 30

rG-CSF- Their Influence on Preterm Infants with Sepsis 30

Serum Macrophage Colony Stimulating Growth Factors Associated

with Thrombocyte and Monocyte 30

Src Pathway Inactivation in Kit Impairs Blood Cell Growth and

Proliferation 30

Cole Eye Institute Offers TIMP-3 Mechanism for Preventing

Abnormal Growth of Blood Vessels 31

Effect of Brain Derived Neurotrophic Factor on Retinal Cells 31

Orcel™ Exhibits High Growth Factor for Wound Healing and

Cardiovascular Applications 32

Drug Combination of Macrophage Colony Stimulating Factor Shows

Successful Tolerance Levels 32

Neotrofin™ Triggers Neurotrophic Factors 32

G-CSF Shows Capability for Promoting Neutrophil Production 33

Insulin-like Growth Factor-1 (IGF) Gene Transfer Accelerates

Wound Healing Process 33

Hepatocyte Growth Factors - Exhibiting Dual Role 34

Cortex Pharmaceuticals Ampakines® Promotes Expression of

Neurotrophin 34

Granulocyte Colony Stimulating Factor Finds Application in

Treating Neonates 34

Cerebrolysin Promotes Cognition 34

7. BREAKTHROUGHS - A RECENT PAST REVIEW 35

Novel Set of Human Cytokines Unveiled 35

IGFBP-3 and its Potential to Ward Off Gastric Cancer 35

Bone Morphogenic Proteins Show Potential for Musculoskeletal

Regeneration 35

Growth Factors - Their Role in Preventing Heart Stroke 35

Growth Factor Proteins Show Promising Results for Treating Cancer 35

Neurotrophic Growth Factor - Primarily Responsible for Loss of

Vision 36

Redox-Active Grape Seed Exhibits Favorable Properties for

Dermal Wound Healing 36

Role of Brain-Derived Neurotrophic Factor on Memory 36

Nerve Growth Factor Found to Enhance Barium Current and

Insulin Secretion 36

Lipid Peroxidation May be Associated with Wound Healing 37

Genentech Inc Unveils Molecule for Stimulating Growth of Blood

Vessels 37

Connective Tissue Growth Factor Found to Promote Lung Fibroblast 37

Influence of Insulin-Like Growth Factor on Growth 38

Regeneron Discovers Angiopoietins Targeted at Blood Vessel

Growth and Repair 38

Environment and Insulin-Like Growth Factors Stimulate Risk of

Cancer 38

Cocktail of Neurotrophic Factors Promotes Regeneration of Torn

Nerves 38

Growth Factors Administration to Stimulate Tissue Repair 39

Cytokine - Their Role in Combating Hepatitis C Virus 39

Axokine® Yields Favorable Results Against Obesity 39

Cell Genesys Unveils GDNF Gene Therapy Targeted Against

Parkinson's Disease 39

8. PRODUCT LAUNCHES 40

Sandoz Unveils Zarzio 40

Wockhardt Launches Three Biotechnology Products 40

Extavia® Receives Approval from European Commission 40

Amgen Bags EC Approval on Use of Aranesp(R) in Paediatric

Patients 41

Hospira Receives EC Approval on Retacrit 41

Tercica Receives FDA Approval For Increlex 41

Ventria Bioscience Introduces Lacromin 41

Dragon Pharmaceuticals Bags Market Approval from Chinese SDA 41

DPI Receives Approvals for Erythropoietin in Three New Markets 42

Wockhardt Introduces Wepox Recombinant Erythropoietin Drug 42

Shanta Biotechnics Unveils Shanferon 42

SkinMedica Unveils TNS Recovery Complex™ Gel 42

CellGenix Unveils Cytokines for Cell Applications 42

Cel-Sci Corporation Develops Multikine 43 Wockhardt Limited

Unveils EPOX™ 43

9. RECENT INDUSTRY ACTIVITY 44

Soluble Systems Collaborates with LifeNet Health's Subsidiary

to Introduce TheraSkin™ 44

GlaxoSmithKline and JCR Pharmaceuticals Enters into Partnership 44

Kaken Pharmaceutical Enters into Licensing Agreement with

Olympus Corporation 44

Biovitrum and Amgen Sign Agreement 45

Merck Establishes Production Unit 45

Eli Lilly and Company Acquires ImClone Systems 45

GeneMedix Changes Name to Reliance GeneMedix 46

FDA Approves Label Expansion for VIDAZA 46

Pfizer Inks Exclusive Global Licensing Agreement with Scil

Technology 46

ZGEN Initiates Ph II Trial of Interleukin 21 47

FzioMed Bags Health Canada Approval on Oxiplex® 47

NsGene A/S Implants Encapsulated Cell in Patients 47

10. INDUSTRY ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER 48

Reliance Life Sciences Takes Over Genemedix 48

Fraunhofer Institute Introduces First Interferon Beta 1a to

Treat Multiple Sclerosis 48

Shanghai Wanxing Inks Export Deal for Recombinant Human

Interferon 48

Hemispherx Enters into Distribution Agreement with Armada 49

Bayer Establishes US Pharmaceuticals Subsidiary 49

Merck Inks Agreement with Bristol-Myers Squibb and ImClone 49

CoGenesys Signs Global Licensing Agreement with Vegenics 49

InterMune Inks New Supply Deal with Boehringer Ingelheim 50

Boston Life Sciences Adopts New Name of Alseres Pharmaceuticals 50

Cambrex Divests Bioproducts and Biopharma Subsidiaries 50

Dragon Divests EPO Business 51

Caregene and Genzyme Forms Partnership to Develop Cere-120 51

NsGene to Undertake Phase Ib Clinical Trial of NsG0202 51

Roche Receives European approval for NeoRecormon 51

Bolder Receives Two U.S. Patents for Hematopoietic Factors 52

RLS to Initiate Clinical Trials of Erythropoietin 52

InterMune Drops Phase III trial of Interferon 52

Chugai to Conduct Additional Trial on Epogin® 52

Merck KGaA Acquires Serono Labs 52

CytoPharm Acquires Low-Dose Interferon License from Amarillo

Biosciences 53

Hospira Signs Agreements with STADA and BIOCEUTICALS for

Erythropoietin 53

Biocon Bags GEAC Approval to Conduct Clinical Trial of

Granulocyte Colony Stimulating Factor 53

SII to Conduct Clinical Trials of Rdna Products 53

Claris to Construct Production Facility for EOP 54

Mayne and Pliva to End Collaboration on Erythropoietin

Development 54

GeneMedix Collaborates with CJ Corp. 54

FzioMed and USC Enter into Licensing Agreement for Oligopeptides 54

AnGes MG Enters Into An Agreement with Vical 55

Corautus and BIA Sign Agreement for VEGF-2 plasmid DNA 55

Dragon Pharmaceuticals Acquires Oriental Wave 55

Insmed Enters into Exclusive Agreement with UCSF for IGF-1 Series 55

Amrad and Ludwig Institute Jointly Focus on the Development of

VEGF-B 55

GeneMedix Restructures Business 56

pSivida Limited Collaborates with Ian Wark Research Institute 56

Amgen Acquires Tularik 56

BMPI Signs up Luitpold Pharmaceuticals for FDA Approved GEM 21S™ 56

Chugai and Roche Expand Drug Research Synergies 56

Dragon Pharmaceuticals to Construct New Production Facility 57

FibroGen Signs Contract with Yamanouchi for Licensing EPO

Small Molecule 57

Insmed and Tzamal Pharma Sign Agreement for Promoting SomatoKine 57

Maxygen and Rentschler Enter into a Contract for G-CSF 57

Maxygen Signs Agreement with Biovitrum for Manufacturing Beta

Interferon 57

Dragon Pharmaceuticals Signs Agreement with Zhongkai 58

Dragon Pharmaceuticals Enters into Definitive Agreement with

Oriental Wave 58

Zymogenetics Bags US FDA Clearance 58

Ceregene Bags Patent 58

AME Enters into Third Collaboration with Eli Lilly and Company 58

ViaCell Enters into Licensing Agreement and Collaboration with

Amgen 59

Ceregene Enters into Licensing Agreement with Genentech 59

BIOPHARM GmbH Enters into Licensing Contract with DePuy 59

Maxygen Enters into a Deal with Roche Holding 59

GeneMedix Signs Agreement with SkyePharma 60

Neurotech Enters into Licensing Agreement with Amgen 60

Ceregene Enters into a Licensing Agreement with Washington

University 60

NeoTherapeutics Receives US Patent for Stimulating Neuritogenesis 60

BioSET Bags Global Exclusive License for Novel Growth Factor

Technology 60

ViaCell Acquires Cerebrotec 60

Fibrogen Collaborates with Sankyo 61

Prescient NeuroPharma Collaborates with SRIB 61

Dragon Pharmaceuticals Signs Agreement with Renapharm AB and

Transworld 61

Baxter Bags Exclusive Worldwide Rights for Epoetin Omega 61

Ortec International Bags FDA PMA for OrCel 61

GeneMedix Bags Chinese SDA Approval 62

NsGene Collaborates with ARIAD Pharmaceuticals 62

Regeneron Enters into Agreement with Emisphere Technologies 62

NsGene A/S Signs Agreement with Biogen Inc 62

NTB Enters into BioInformatics Outsourcing Agreement with HSC 63

11. FOCUS ON SELECT GLOBAL PLAYERS 64

Alseres Pharmaceuticals, Inc. (USA) 64

Amgen, Inc. (USA) 64

Bayer HealthCare Pharmaceuticals Inc. (USA) 64

BioMimetic Therapeutics, Inc. (USA) 65

Biopharm GmbH (Germany) 65

Bolder Biotechnology, Inc. (USA) 65

Ceregene, Inc. (USA) 65

FibroGen, Inc. (USA) 66

FzioMed, Inc. (USA) 66

Novo Nordisk A/S (Denmark) 66

Reliance GeneMedix Plc. (UK) 66

Insmed, Inc. (USA) 67

Johnson & Johnson (USA) 67

Janssen-Ortho, Inc. (Canada) 68

Lonza Group (Switzerland) 68

Maxygen, Inc. (USA) 68

Merck Serono International S.A. (Switzerland) 69

NsGene A/S (Denmark) 69

PeproTech, Inc. (USA) 69

Rentschler Biotechnologie GmbH (Germany) 69

F. Hoffmann-La Roche Ltd (Switzerland) 70

Chugai Pharmaceutical Co. Ltd. (Japan) 70

Genentech, Inc. (USA) 70

Shantha Biotechnics (India) 71

Scil Proteins GmbH (Germany) 71

Wockhardt Ltd. (India) 71

12. GLOBAL MARKET PERSPECTIVE 72

Table 7: World Recent Past, Current & Future Analysis for

Growth Factors (Blood and Tissue) by Geographic Region - US,

Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Sales in US$ Million for Years 2007

through 2015 (includes corresponding Graph/Chart) 72

Table 8: World Historic Review for Growth Factors (Blood and

Tissue) by Geographic Region - US, Japan, Europe, and Rest of

World Markets Independently Analyzed with Annual Sales in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 73

Table 9: World 11-Year Perspective for Growth Factors (Blood

and Tissue) by Geographic Region - Percentage Breakdown of

Value Sales for US, Japan, Europe, and Rest of World Markets

for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 74

Table 10: World Recent Past, Current & Future Analysis for

Blood Growth Factors by Geographic Region - US, Japan, Europe,

and Rest of World Markets Independently Analyzed with Annual

Sales in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 75

Table 11: World Historic Review for Blood Growth Factors by

Geographic Region - US, Japan, Europe, and Rest of World

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 76

Table 12: World 11-Year Perspective for Blood Growth Factors

by Geographic Region - Percentage Breakdown of Value Sales for

US, Japan, Europe, and Rest of World Markets for 2005, 2010 &

2015 (includes corresponding Graph/Chart) 77

Table 13: World Recent Past, Current & Future Analysis for

Blood Growth Factors by Type - Erythropoietins, Colony

Stimulating Factors, Interferons and Interleukins Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) 78

Table 14: World Historic Review for Blood Growth Factors by

Type - Erythropoietins, Colony Stimulating Factors,

Interferons and Interleukins Markets Independently Analyzed

with Annual Sales in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 79

Table 15: World 11-Year Perspective for Blood Growth Factors

by Type - Percentage Breakdown of Value Sales for

Erythropoietins, Colony Stimulating Factors, Interferons and

Interleukins Markets for 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 80

Table 16: World Recent Past, Current & Future Analysis for

Erythropoietins by Geographic Region - US, Japan, Europe, and

Rest of World Markets Independently Analyzed with Annual Sales

in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 81

Table 17: World Historic Review for Erythropoietins by

Geographic Region - US, Japan, Europe, and Rest of World

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 82

Table 18: World 11-Year Perspective for Erythropoietins by

Geographic Region - Percentage Breakdown of Value Sales for

US, Japan, Europe, and Rest of World Markets for 2005, 2010 &

2015 (includes corresponding Graph/Chart) 83

Table 19: World Recent Past, Current & Future Analysis for

Colony Stimulating Factors by Geographic Region - US, Japan,

Europe, and Rest of World Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 84

Table 20: World Historic Review for Colony Stimulating Factors

by Geographic Region - US, Japan, Europe, and Rest of World

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 85

Table 21: World 11-Year Perspective for Colony Stimulating

Factors by Geographic Region - Percentage Breakdown of Value

Sales for US, Japan, Europe, and Rest of World Markets for

2005, 2010 & 2015 (includes corresponding Graph/Chart) 86

Table 22: World Recent Past, Current & Future Analysis for

Interferons as Blood Growth Factors by Geographic Region - US,

Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Sales in US$ Million for Years 2007

through 2015 (includes corresponding Graph/Chart) 87

Table 23: World Historic Review for Interferons as Blood

Growth Factors by Geographic Region - US, Japan, Europe, and

Rest of World Markets Independently Analyzed with Annual Sales

in US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 88

Table 24: World 11-Year Perspective for Interferons as Blood

Growth Factors by Geographic Region - Percentage Breakdown of

Value Sales for US, Japan, Europe, and Rest of World Markets

for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 89

Table 25: World Recent Past, Current & Future Analysis for

Interleukins as Blood Growth Factors by Geographic Region -

US, Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Sales in US$ Million for Years 2007

through 2015 (includes corresponding Graph/Chart) 90

Table 26: World Historic Review for Interleukins as Blood

Growth Factors by Geographic Region - US, Japan, Europe, and

Rest of World Markets Independently Analyzed with Annual Sales

in US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 91

Table 27: World 11-Year Perspective for Interleukins as Blood

Growth Factors by Geographic Region - Percentage Breakdown of

Value Sales for US, Japan, Europe, and Rest of World Markets

for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 92

Table 28: World Recent Past, Current & Future Analysis for

Tissue Growth Factors by Geographic Region - US, Japan,

Europe, and Rest of World Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 93

Table 29: World Historic Review for Tissue Growth Factors by

Geographic Region - US, Japan, Europe, and Rest of World

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 94

Table 30: World 11-Year Perspective for Tissue Growth Factors

by Geographic Region - Percentage Breakdown of Value Sales for

US, Japan, Europe, and Rest of World Markets for 2005, 2010 &

2015 (includes corresponding Graph/Chart) 95

13. THE UNITED STATES 96

A. Market Analysis 96

Current and Future Analysis 96

Leading EPO Drugs in the US 96

B. Market Analytics 97

Table 31: US Recent Past, Current & Future Analysis for

Growth Factors by Type - Blood Growth Factors

(Erythropoietins, Colony Stimulating Factors, Interferons

and Interleukins) and Tissue Growth Factors Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) 97

Table 32: US Historic Review for Growth Factors by Type -

Blood Growth Factors (Erythropoietins, Colony Stimulating

Factors, Interferons and Interleukins) and Tissue Growth

Factors Markets Independently Analyzed with Annual Sales in

US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 98

Table 33: US 11-Year Perspective for Growth Factors by Type -

Percentage Breakdown of Value Sales for Blood Growth

Factors (Erythropoietins, Colony Stimulating Factors,

Interferons and Interleukins) and Tissue Growth Factors

Markets for 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 99

14. JAPAN 100

A. Market Analysis 100

Current and Future Analysis 100

Erythropoietin Market 100

Leading EPO Drugs in Japan 100

Market Scenario for Biotech Products 100

Biotech Market Backed by Public Assistance 100

B. Market Analytics 101

Table 34: Japanese Recent Past, Current & Future Analysis

for Growth Factors by Type - Blood Growth Factors

(Erythropoietins, Colony Stimulating Factors, Interferons

and Interleukins) and Tissue Growth Factors Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) 101

Table 35: Japanese Historic Review for Growth Factors by

Type - Blood Growth Factors (Erythropoietins, Colony

Stimulating Factors, Interferons and Interleukins) and

Tissue Growth Factors Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 102

Table 36: Japanese 11-Year Perspective for Growth Factors by

Type - Percentage Breakdown of Value Sales for Blood Growth

Factors (Erythropoietins, Colony Stimulating Factors,

Interferons and Interleukins) and Tissue Growth Factors

Markets for 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 103

15. EUROPE 104

A. Market Analysis 104

Current and Future Analysis 104

Erythropoietin Market Scenario in the Recent Past 104

Leading EPO Drugs in Europe 104

B. Market Analytics 105

Table 37: European Recent Past, Current & Future Analysis

for Growth Factors by Type - Blood Growth Factors

(Erythropoietins, Colony Stimulating Factors, Interferons

and Interleukins) and Tissue Growth Factors Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) 105

Table 38: European Historic Review for Growth Factors by

Type - Blood Growth Factors (Erythropoietins, Colony

Stimulating Factors, Interferons and Interleukins) and

Tissue Growth Factors Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 106

Table 39: European 11-Year Perspective for Growth Factors by

Type - Percentage Breakdown of Value Sales for Blood Growth

Factors (Erythropoietins, Colony Stimulating Factors,

Interferons and Interleukins) and Tissue Growth Factors

Markets for 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 107

16. REST OF WORLD 108

A. Market Analysis 108

Current and Future Analysis 108

An Overview of Indian Market 108

Erythropoietin 108

G-CSF Market 109

Interferon 109

B. Market Analytics 110

Table 40: Rest of World Recent Past, Current & Future

Analysis for Growth Factors by Type - Blood Growth Factors

(Erythropoietins, Colony Stimulating Factors, Interferons

and Interleukins) and Tissue Growth Factors Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) 110

Table 41: Rest of World Historic Review for Growth Factors

by Type - Blood Growth Factors (Erythropoietins, Colony

Stimulating Factors, Interferons and Interleukins) and

Tissue Growth Factors Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 111

Table 42: Rest of World 11-Year Perspective for Growth

Factors by Type - Percentage Breakdown of Value Sales for

Blood Growth Factors (Erythropoietins, Colony Stimulating

Factors, Interferons and Interleukins) and Tissue Growth

Factors Markets for 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 112

COMPETITIVE LANDSCAPE

Total Companies Profiled: 88 (including Divisions/Subsidiaries - 100)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 54

Canada 3

Japan 5

Europe 21

Germany 11

The United Kingdom 2

Rest of Europe 8

Asia-Pacific (Excluding Japan) 14

Middle-East 3

------------------------------------------

To order this report:: Global Growth Factors ( Blood And Tissue ) Industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:  Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response
2. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
3. Forward step in forecasting global warming
4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
5. Bionovo to Present at Canaccord Adams Global Growth Conference
6. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
7. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
8. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
9. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
10. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
11. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... ... Supplyframe, the Industry Network for electronics hardware design and ... in Pasadena, Calif., the Design Lab’s mission is to bring together inventors and ... brought to market. , The Design Lab is Supplyframe’s physical representation of one ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
Breaking Biology News(10 mins):